Rules-Based Medicine Newswire (Page 7)

Rules-Based Medicine Newswire (Page 7)

Comprehensive Real-Time News Feed for Rules-Based Medicine. (Page 7)

Results 121 - 140 of 406 in Rules-Based Medicine

  1. Myriad Genetics, Inc. (MYGN) Shares Bought by Schwab Charles Investment Management Inc.Read the original story w/Photo

    Apr 24, 2016 | Daily Political

    Schwab Charles Investment Management Inc. increased its position in shares of Myriad Genetics, Inc. by 49.1% during the fourth quarter, Holdings Channel reports. The firm owned 448,192 shares of the company's stock after buying an additional 147,593 shares during the period.

    Comment?

  2. Myriad to Announce Fiscal Third-Quarter 2016 Financial Results on May 3Read the original story w/Photo

    Apr 22, 2016 | GlobeNewswire

    Myriad Genetics, Inc. today announced that it will hold its fiscal third-quarter 2016 sales and earnings conference call with investors and analysts at 4:30 p.m. ET on Tuesday, May 3. During the call, Mark C. Capone, president and CEO and Bryan Riggsbee, chief financial officer, will provide an overview of Myriad's financial performance for the fiscal third-quarter and provide a business update. To listen to the call, interested parties in the United States may dial 888-224-7964 or +1 303-223-4373 for international callers.

    Comment?

  3. Myriad Genetics, Inc. (MYGN) Rating Lowered to Sell at Zacks Investment ResearchRead the original story w/Photo

    Apr 18, 2016 | Daily Political

    According to Zacks, "Myriad has completed the second quarter of fiscal 2016 on an impressive note, with both its top and bottom line comfortably beating the Zacks Consensus Estimate. Further, the timely and successful conversion of its hereditary cancer business to myRisk buoys optimism.

    Comment?

  4. Dr. Fang Xie, Of Counsel, Greenberg Traurig, LLP to Speak at TKG's EventRead the original story w/Photo

    Apr 17, 2016 | PR Log

    April 17, 2016 - PRLog -- The Knowledge Group/The Knowledge Congress Live Webcast Series, the leading producer of regulatory focused webcasts, has announced today that Dr. Fang Xie, Of Counsel, Greenberg Traurig, LLP will speak at the Knowledge Congress' webcast entitled: "Patent Protection for Pharma and Biotechnology in 2016 LIVE Webcast." This event is scheduled for Monday, April 18, 2016 @ 3:00 PM to 5:00 PM .

    Comment?

  5. Nationwide Fund Advisors Raises Stake in Myriad Genetics, Inc.Read the original story w/Photo

    Apr 10, 2016 | Daily Political

    Nationwide Fund Advisors raised its stake in Myriad Genetics, Inc. by 2.0% during the fourth quarter, Holdings Channel reports. The fund owned 45,572 shares of the company's stock after buying an additional 896 shares during the period.

    Comment?

  6. Myriad Genetics, Inc. (MYGN) VP Gary A. King Sells 15,000 SharesRead the original story w/Photo

    Apr 5, 2016 | AmericanBankingNews.com

    Myriad Genetics, Inc. VP Gary A. King sold 15,000 shares of the firm's stock in a transaction on Friday, April 1st. The shares were sold at an average price of $38.12, for a total transaction of $571,800.00.

    Comment?

  7. A Systemic Look At SchizophreniaRead the original story

    Jan 19, 2010 | Today's Chemist At Work

    ... She and her coworkers have identified schizophrenia biomarkers in serum, and working with the company Rules-Based Medicine, located in Austin, Texas, and Lake Placid, N.Y., she expects that a serum-based test to aid in the diagnosis of schizophrenia ...

    Comment?

  8. Myriad myRisk Hereditary Cancer test identifies 70% more deleterious...Read the original story w/Photo

    Mar 31, 2016 | Medical News

    Prospective Clinical Study Showed the myRisk Test Identified 70 Percent More Deleterious Mutations than BRCA Testing Alone with 42 Percent of These in Women Over Age 45 Myriad Genetics, Inc. , a leader in molecular diagnostics and personalized medicine, working in collaboration with researchers from the Harvard Medical School, today announced that the Journal of Clinical Oncology has published a paper showing the frequency of germline mutations in 25 cancer susceptibility genes among patients with breast cancer.

    Comment?

  9. Myriad myRisk Hereditary Cancer Article in Journal of Clinical...Read the original story

    Mar 30, 2016 | PressReleasePoint

    Myriad Genetics , Inc. , a leader in molecular diagnostics and personalized medicine, working in collaboration with researchers from the Harvard Medical School, today announced that the Journal of Clinical Oncology has published a paper showing the frequency of germline mutations in 25 cancer susceptibility genes among patients with breast cancer. "This is the first study to show the frequency of germline mutations in BRCA1/2 and other breast cancer predisposition genes in a sequential series of breast cancer patients prospectively collected and unselected for family history or age," said Anne-Renee Hartman, M.D., an author of the publication and senior vice president of clinical development at Myriad Genetic Laboratories.

    Comment?

  10. Predictive Breast Cancer Gene Testing Market to Rise Due to...Read the original story w/Photo

    Mar 29, 2016 | SBWire

    A new market research report by Transparency Market Research, titled " Predictive Breast Cancer Gene Testing Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019", presents an in-depth analysis of the market and helps in identifying the unmet needs within the market along with highlighting the attitude of physicians towards the present condition of gene testing. The changes expected to take place in the predictive breast cancer gene testing market in the coming years owing to a number of swift technological developments have also been presented in this report.

    Comment?

  11. Myriad Genetics, Inc. (MYGN) Short Interest UpdateRead the original story w/Photo

    Mar 27, 2016 | AmericanBankingNews.com

    Myriad Genetics, Inc. was the target of a large decrease in short interest in March. As of March 15th, there was short interest totalling 17,478,486 shares, a decrease of 10.9% from the February 29th total of 19,618,848 shares, MarketBeat reports.

    Comment?

  12. Goldman Sachs Raises Myriad Genetics, Inc. (MYGN) Price Target to $40.00Read the original story w/Photo

    Mar 23, 2016 | AmericanBankingNews.com

    Goldman Sachs' target price suggests a potential upside of 9.92% from the company's previous close. Shares of Myriad Genetics traded down 2.10% during midday trading on Wednesday, reaching $36.39.

    Comment?

  13. Myriad Genetics Teams Up With To Educate The Public About Hereditary Cancer And Genetic TestingRead the original story

    Mar 20, 2016 | BioSpace

    Myriad Genetics , Inc. , a leader in molecular diagnostics and personalized medicine, and Access Health A , an educational program focused on health and wellness, today announced that they will air an educational program on hereditary cancer that will appear on LifetimeA . The program, titled " Hereditary Cancer Risk Assessment and Testing: The Answer Is in Your DNA, " will run on Wednesday, March 30, 2016 7:30 am and again on Wednesday, April 6, 2016 7:30 am .

    Comment?

  14. Myriad Genetics Teams Up with Access Health to Educate the Public...Read the original story

    Mar 21, 2016 | PressReleasePoint

    Myriad Genetics , Inc. , a leader in molecular diagnostics and personalized medicine, and Access Health A , an educational program focused on health and wellness, today announced that they will air an educational program on hereditary cancer that will appear on LifetimeA . The program, titled " Hereditary Cancer Risk Assessment and Testing: The Answer Is in Your DNA, " will run on Wednesday, March 30, 2016 7:30 am and again on Wednesday, April 6, 2016 7:30 am .

    Comment?

  15. The Myriad myRisk Hereditary Cancer Test Identifies 60 Percent More...Read the original story

    Mar 18, 2016 | PressReleasePoint

    Myriad Genetics , Inc. , a leader in molecular diagnostics and personalized medicine, today announced it will present two important new studies at the 2016 Society for Gynecologic Oncology annual meeting in San Diego, Calif. The data demonstrate the ability of the myRiskA Hereditary Cancer test to identify deleterious mutations in patients with endometrial cancer.

    Comment?

  16. Myriad Genetics Presents Second Pivotal Validation Study For Its Mypath Melanoma TestRead the original story

    Mar 14, 2016 | BioSpace

    Myriad Genetics , Inc. , a leader in molecular diagnostics and personalized medicine, today announced the results from the second pivotal clinical validation study for the myPathA Melanoma test at the 2016 USCAP Annual Meeting in Seattle, Wash. "There is significant emotional distress associated with a melanoma diagnosis and doctors want to provide their patients with accurate information," said Loren Clarke, M.D., medical director, Myriad Genetic Laboratories.

    Comment?

  17. Myriad Presents Second Pivotal Validation Study for Its myPath Melanoma TestRead the original story

    Mar 15, 2016 | PressReleasePoint

    Myriad Genetics , Inc. , a leader in molecular diagnostics and personalized medicine, today announced the results from the second pivotal clinical validation study for the myPathA Melanoma test at the 2016 USCAP Annual Meeting in Seattle, Wash. There is significant emotional distress associated with a melanoma diagnosis and doctors want to provide their patients with accurate information, " said Loren Clarke, M.D., medical director, Myriad Genetic Laboratories.

    Comment?

  18. Myriad Genetics, Inc. (Mygn) Stake Reduced by Iridian Asset Management LLC CTRead the original story w/Photo

    Mar 15, 2016 | AmericanBankingNews.com

    Iridian Asset Management LLC CT decreased its position in Myriad Genetics, Inc. by 26.3% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 3,891,072 shares of the company's stock after selling 1,389,236 shares during the period.

    Comment?

  19. Myriad Genetics, Inc. (MYGN) Shares Sold by Profund Advisors LLCRead the original story w/Photo

    Mar 11, 2016 | AmericanBankingNews.com

    Profund Advisors LLC lowered its stake in Myriad Genetics, Inc. by 0.6% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 50,947 shares of the company's stock after selling 296 shares during the period.

    Comment?

  20. Tieton Capital Management LLC Sells 22,120 Shares of Myriad Genetics, Inc.Read the original story w/Photo

    Mar 11, 2016 | AmericanBankingNews.com

    Tieton Capital Management LLC lowered its position in shares of Myriad Genetics, Inc. by 15.6% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 119,290 shares of the company's stock after selling 22,120 shares during the period.

    Comment?